Quercetin

The VerdictMODERATE CONVICTIONWorth-It: Low ROI (53/100)

Quercetin works modestly for blood pressure, blood sugar, and inflammation in people who already have those problems.

Quercetin for "general wellness" or daily anti-aging? Skip it. The senolytic and antihistamine pitches are mechanism-only at consumer dose. Save the £15 a month for protein, sleep, or training.

Quercetin lowers blood pressure by about 3 mmHg, modestly improves blood sugar, and reduces CRP by about a third of a milligram per litre — but only at 500 mg or more per day for at least 8 weeks AND only in adults who already have hypertension, type 2 diabetes, metabolic syndrome, or chronic inflammation.
The "natural antihistamine" and "senolytic anti-aging" pitches are not supported by human chronic-dose trials. Mast cell evidence is in test tubes; senolytic trials use dasatinib + quercetin together, intermittently, in disease populations.
If you have a metabolic-disease indication and your prescriber agrees: 500–1,000 mg per day of plain aglycone or phytosome quercetin with the largest meal, for at least 8 weeks. About one to two capsules. Track BP, fasting glucose, CRP at baseline and 12 weeks.

That's the general answer. Your stack is different.

Check your whole stack

The Protocol

Population	Dose	Timing	Form	Duration
Hypertension adjunct (under medical oversight)	500–1,000 mg/day	With largest meal	Aglycone or phytosome	≥8 weeks
T2D / metabolic syndrome adjunct	500–1,000 mg/day	With main meal	Aglycone or phytosome	≥8 weeks
Elevated CRP / chronic inflammation	500–1,000 mg/day	With food	Aglycone or phytosome	≥8 weeks
Acute outpatient COVID-19 (physician-supervised)	500–1,000 mg/day phytosome	With food	Phytosome (most trials)	14–30 days
Endurance pre-event (small effect)	500–1,000 mg/day	30–60 min pre-exercise	Aglycone	1–2 weeks pre-event
Healthy adult prophylactic	NOT RECOMMENDED	—	—	—
Senolytic anti-aging via daily monotherapy	NOT TESTED — research uses D+Q intermittent only	—	—	—

Forms — head-to-head

Aglycone

Bioavailability low (<10%); high inter-individual variability

Most cardiometabolic RCT-equivalent dosing

£10–25/month at 500–1,000 mg

Phytosome (Quercefit)

2–10× plasma AUC vs aglycone

Acute COVID-19 trials, some BP studies

£25–60/month — premium

EMIQ

Higher AUC than aglycone in single-dose PK

Allergic-rhinitis exploratory trials only

£15–40/month

Glycosides (rutin, isoquercitrin)

Higher than aglycone for some glycosides

Food-equivalent dosing

£10–30/month

Liposomal

No comparative outcome RCT

Premium pricing without outcome evidence

£40–80/month — not justified

Absorption tips

Take with a fat-containing meal. Avoid taking with high-bran or high-fiber meals (reduces absorption). Iron, copper, and zinc absorption can be reduced when taken simultaneously with high-dose quercetin via chelation — separate dosing by 2 hours. Phytosome forms only justify the price premium where the relevant RCT used phytosome (acute COVID, some BP trials).

Safety & Interactions

Warfarin, DOACs MODERATE

CYP2C9 inhibition + antiplatelet activity → potential altered INR / bleeding. Avoid or monitor INR closely under prescriber oversight.

Cyclosporine, tacrolimus, narrow-TI CYP3A4 / P-gp substrates MODERATE

Potential ↑ plasma drug concentration via intestinal CYP3A4 and P-glycoprotein inhibition. Avoid or monitor levels.

Active chemotherapy (doxorubicin, cisplatin, others) MODERATE

Antioxidant interaction concern with ROS-dependent regimens. Oncology consult required; default avoid.

Hormone-sensitive cancer therapy (tamoxifen, AIs, HRT) MODERATE

Phytoestrogenic activity documented in vitro. Avoid during active treatment unless cleared by oncology.

Antihypertensives, antidiabetics MILD-MODERATE

Additive BP-lowering and hypoglycemic effects at ≥500 mg/day. Monitor BP and glucose if combining.

Iron (non-heme), copper, zinc MILD

Chelation reduces absorption. Separate dosing by 2 hours.

Contraindicated populations

Pregnancy / lactation — data unavailable, avoid supplemental doses
Patients on warfarin / DOACs without prescriber oversight
Patients on cyclosporine / tacrolimus
Active chemotherapy without oncology clearance
Within 1–2 weeks of elective surgery (theoretical bleeding risk)
Active hormone-sensitive cancer treatment without oncology clearance

Side effects

Mild GI upset and nausea reported in <5% of trials at ≤1,000 mg/day. Headache and paraesthesia <5% at 1,000+ mg/day chronic. Acute renal failure has been reported only in single IV gram-dose research cases — not consumer-relevant.

Upper limit

No formal UL established. Dietary intake from food typically 5–40 mg/day. Supplement RCTs commonly use 500–1,000 mg/day with acceptable short-term tolerability up to 12 weeks. Long-term (>6 months) safety at chronic ≥1,000 mg/day is underpowered.

How confident are we?

Moderate

Endpoint-stratified: BP in hypertensives at ≥500 mg/day ≥8 wk MODERATE. Glycemic control in T2D / MetS MODERATE. CRP / TNF-α reduction in metabolic-inflammatory disease MODERATE. Acute outpatient COVID-19 phytosome under physician oversight MODERATE. Lipids in healthy adults DEBUNKED. Endurance in trained athletes WEAK. Allergic rhinitis at chronic supplement dose WEAK. Senolytic anti-aging at daily monotherapy NONE. Cancer prevention / longevity / lifespan NONE. Cognitive enhancement in healthy adults NONE. Liposomal outcome superiority NONE.

What would change this?

A double-blind, placebo-controlled RCT (N≥300, ≥6 months) of standardised quercetin 1,000 mg/day in healthy adults with a hard cardiometabolic endpoint. A phase 2/3 RCT of D+Q intermittent therapy with FEV1 decline, eGFR slope, or 12-month gait speed instead of senescent-cell biomarkers. A double-blind RCT (N≥150, ≥6 weeks) of quercetin (EMIQ or phytosome) in allergic rhinitis with TNSS / RQLQ. A head-to-head outcome RCT (N≥150, ≥12 weeks) of phytosome vs aglycone at matched dose in T2D / MetS with HbA1c primary, showing phytosome superiority at lower mg.

Key Sources

Serban M-C et al., 2016, J Am Heart Assoc. SR + meta-analysis of RCTs on quercetin and BP, N=587, 7 trials. SBP −3.04 mmHg, DBP −2.63 mmHg overall; significant only at ≥500 mg/day. (PMID 27405810)
Tabrizi R et al., 2020, Nutrition Reviews. SR + meta-analysis of RCTs on quercetin effects on plasma lipids, BP, and glucose, 17 trials. (PMID 31940027)
Mohammadi-Sartang M et al., 2017, Eur J Clin Nutr. SR + meta-analysis of RCTs on quercetin and CRP, 7 RCTs N=403. CRP −0.33 mg/L. (PMID 28537580)
Ostadmohammadi V et al., 2019, Phytotherapy Research. SR + meta-analysis of quercetin on glycemic control in MetS and related disorders. (PMID 30848564)
Tabrizi R et al., 2020, Crit Rev Food Sci Nutr. SR + meta-analysis of RCTs on quercetin and lipids + inflammation in metabolic syndrome, 16 RCTs N=886. (PMID 31017459)
Sahebkar A, 2017, Crit Rev Food Sci Nutr. SR + meta-analysis of RCTs on quercetin and plasma lipids, 5 RCTs N=312. Lipid profile null. (PMID 25897620)
Llaha F et al., 2025, Food Chemistry. SR + meta-analysis of human PK studies on quercetin bioavailability and form comparisons. (PMID 40037045)
Kressler J et al., 2011, Med Sci Sports Exerc. SR + meta-analysis of quercetin and endurance exercise capacity. VO2max +1.95%, p=0.009 — clinically trivial. (PMID 21606866)
Di Pierro F et al., 2023, Reviews in Medical Virology. SR + meta-analysis of RCTs on quercetin (incl. phytosome) for COVID-19. 6 RCTs N≈660; phytosome trials industry-adjacent. (PMID 36779438)
Justice JN et al., 2019, EBioMedicine. Open-label phase 1 senolytic safety / feasibility trial of D+Q in IPF, N=14. [cite-unverified] Preflight-sourced.
Hickson LJ et al., 2019, EBioMedicine. Open-label pilot of D+Q in DKD, N=9. [cite-unverified] Preflight-sourced.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

53/100 Low ROI Trust grade C

No - the allergy and immune reasons people buy it are unproven, and the real benefit is a different endpoint in people who already have metabolic disease.

Time

Low

Money

Medium

Effort

Low

Risk

Medium

Why this score

The reason this buyer purchases it fails on evidence: the 'natural antihistamine' claim rests on in vitro mast-cell stabilization, with no meta-analytic chronic-dose RCT for allergic rhinitis, so the allergy and immune benefit is mechanism-only.
The real benefit is a different endpoint in a different population: blood pressure drops about 3 mmHg (Serban 2016, PMID 27405810, N=587), with modest glycemic and CRP improvements (Mohammadi-Sartang 2017, PMID 28537580, CRP -0.33 mg/L), but only in disease populations at 500 mg or more per day for 8+ weeks - healthy adults get nothing measurable.
Money is Medium and largely wasted here: about $13 to $32 a month for aglycone, while the lipid claim in healthy adults is flatly null (Sahebkar 2017, PMID 25897620) and the endurance effect is clinically trivial (Kressler 2011, +1.95% VO2max).
Trust grade is C: a genuine but narrow disease-state signal surrounded by debunked and mechanism-only consumer claims, with the COVID trials (Di Pierro 2023) being acute therapeutic and physician-supervised, not the prophylactic immune use people imagine.
Risk is Medium, not Low: quercetin inhibits CYP3A4 and CYP2C9 and has antiplatelet activity, so it matters for anyone on warfarin, DOACs, cyclosporine, tacrolimus, chemotherapy, or facing surgery - that interaction profile caps the band.

Why it didn’t score higher

Allergy, immune, and 'general wellness' - the reasons this audience buys - have no human outcome RCT at consumer dose.
Every real effect is confined to people who already have hypertension, type 2 diabetes, metabolic syndrome, or elevated CRP, which is not the stated buyer.
Poor aglycone absorption plus a Medium-risk drug-interaction profile mean the typical bottle delivers little while still carrying real interaction concerns.

Best for

Adults with hypertension on first-line therapy seeking a small BP adjunct, at 500 to 1,000 mg/day for 8+ weeks under medical oversight
Adults with type 2 diabetes or metabolic syndrome seeking adjunct glycemic and inflammatory marker improvement
Adults with elevated chronic inflammation (high CRP) at 500 to 1,000 mg/day for 8+ weeks
Outpatient adults with acute COVID-19 under physician oversight where a phytosome form is available

Lower ROI if

You are a healthy adult buying it for allergies, immunity, anti-aging, or general wellness - the evidence does not support these
You take a low typical dose of 50 to 250 mg/day, below the 500 mg threshold where anything moved in trials
You buy plain aglycone and assume it absorbs like the phytosome forms used in some trials
You are on warfarin, a DOAC, cyclosporine, tacrolimus, chemotherapy, or planning surgery within 1 to 2 weeks

Minimum effective dose

500 to 1,000 mg/day of aglycone or phytosome quercetin, with the largest meal, for at least 8 weeks, in a diagnosed cardiometabolic or inflammatory indication only. For allergy, immune, or general-wellness goals there is no evidence-based dose.

Track this

Blood pressure, fasting glucose, and CRP at baseline and 8 to 12 weeks if you are in a disease subgroup - discontinue if no change
Honestly nothing reliable for the allergy or immune goal, since no validated clinical endpoint responds at consumer dose
Whether your product specifies a form (aglycone, phytosome, EMIQ) rather than just 'quercetin 500 mg'